The amount represents amortization of intellectual property license fee.

No definition available.

Name:	txmd_AmortizationOfIntellectualPropertyLicenseFee
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Annual net sale milestones in the Territory per license agreement.

+ References

No definition available.

+ Details

Name:	txmd_AnnualNetSalesMilestone
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent.

+ References

No definition available.

+ Details

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.

+ References

No definition available.

+ Details

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from license agreement.

+ References

No definition available.

+ Details

Name:	txmd_CashUpfrontPaymentReceived
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.

+ References

No definition available.

+ Details

Name:	txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of milestone payment received upon regulatory approval.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentReceivedUponRegulatoryApproval
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of milestone payments upon FDA approval.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentUponFDAApproval
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payments payable after release of first commercial batch.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments due upon specified levels of cumulative net sales for under agreement.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.

+ References

No definition available.

+ Details

Name:	txmd_MinimumCashBalanceRequirementUnderCreditAgreement
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment.

+ References

No definition available.

+ Details

Name:	txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The net sales amount as defined in license agreement for step-based royalty payments.

+ References

No definition available.

+ Details

Name:	txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of issued patents domestic.

+ References

No definition available.

+ Details

Name:	txmd_NumberOfIssuedPatentsDomestic
Namespace Prefix:	txmd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of issued patents foreign.

+ References

No definition available.

+ Details

Name:	txmd_NumberOfIssuedPatentsForeign
Namespace Prefix:	txmd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The percentage of quarterly royalty payments on net sales which the company is entitled to receive.

+ References

No definition available.

+ Details

Name:	txmd_QuarterlyRoyaltyPaymentsPercentage
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.

+ References

No definition available.

+ Details

Name:	txmd_RegulatoryMilestoneAdditionalPayment
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Period the company accepts returns of unsalable prescription products from customers following product expiration.

+ References

No definition available.

+ Details

Name:	txmd_ReturnPeriodOfUnsalablePrescriptionProducts
Namespace Prefix:	txmd_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percent of the net sales to be paid as royalty per license agreement.

+ References

No definition available.

+ Details

Name:	txmd_RoyaltyPercent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of sales milestone payments per licensing agreement.

+ References

No definition available.

+ Details

Name:	txmd_SalesMilestonePaymentsInTranches
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Period shelf life of prescription products from date of manufacture.

+ References

No definition available.

+ Details

Name:	txmd_ShelfLifeOfPrescriptionProducts
Namespace Prefix:	txmd_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount represents specified level one of cumulative net sales for milestone payments.

+ References

No definition available.

+ Details

Name:	txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount represents specified level three of cumulative net sales for milestone payments.

+ References

No definition available.

+ Details

Name:	txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount represents specified level two of cumulative net sales for milestone payments.

+ References

No definition available.

+ Details

Name:	txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848

+ Details

Name:	us-gaap_AdvertisingExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.

+ References

No definition available.

+ Details

Name:	us-gaap_CashFDICInsuredAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314

+ Details

Name:	us-gaap_InventoryWriteDown
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ProductInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name:	us-gaap_PropertyPlantAndEquipmentUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=txmd_BijuvaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=txmd_VitaminsImvexxyAndBijuvaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)				1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 05, 2019 EUR (€)	Aug. 05, 2019 USD ($)	Jun. 06, 2019 EUR (€)	Jun. 06, 2019 EUR (€)	Dec. 31, 2020 USD ($) Number $ / shares	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($) Number $ / shares	Dec. 31, 2019 USD ($) $ / shares	Dec. 31, 2018 USD ($)	Nov. 08, 2020 USD ($)
Product Information [Line Items]
Inventory charge						$ 5,700,000	$ 7,204,818	$ 0
Minimum cash balance requirement under credit agreement					$ 60,000,000		60,000,000
Cash FDIC insured amount					$ 250,000		$ 250,000
Number of issued patents domestic. \| Number					38		38
Number of issued patents foreign \| Number					39		39
Write off of patent and trademark cost					$ 500,000	$ 600,000	$ 1,131,776	$ 78,864
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.001		$ 0.001	$ 0.001
Amortization of intellectual property license fee							$ 3,024,391	$ 778,692
Advertising expense							$ 35,799,313	$ 9,045,571	$ 1,682,746
Council License Agreement [Member]
Product Information [Line Items]
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent							50.00%
Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent							20.00%
Maximum costs and expenses for post approval							$ 20,000,000
Council License Agreement Step 1
Product Information [Line Items]
Royalty (percent)							5.00%
Council License Agreement Step 2
Product Information [Line Items]
Royalty (percent)							10.00%
Council License Agreement Step 3
Product Information [Line Items]
Royalty (percent)							15.00%
License Agreement Theramex [Member]
Product Information [Line Items]
Cash upfront payment received	€ 14,000,000	$ 15,506,400
Minimum [Member] \| Council License Agreement Step 2
Product Information [Line Items]
Net sales amount per step-based royalty							$ 500,000
Minimum [Member] \| Council License Agreement Step 3
Product Information [Line Items]
Net sales amount per step-based royalty							$ 1,500,000
Minimum [Member] \| License Agreement Theramex [Member]
Product Information [Line Items]
Sales milestone \| €			€ 25,000,000
Maximum [Member]
Product Information [Line Items]
Return period of unsalable prescription products							12 months
Maximum [Member] \| Council License Agreement Step 1
Product Information [Line Items]
Net sales amount per step-based royalty							$ 500,000
Maximum [Member] \| Council License Agreement Step 2
Product Information [Line Items]
Net sales amount per step-based royalty							$ 1,500,000
Maximum [Member] \| License Agreement Theramex [Member]
Product Information [Line Items]
Regulatory milestone payments \| €			2,000,000	€ 2,000,000
Sales milestone payment \| €			27,500,000	€ 27,500,000
Sales milestone \| €			€ 100,000,000
Land and Building [Member] \| Minimum [Member]
Product Information [Line Items]
Useful life of assets							3 years
Land and Building [Member] \| Maximum [Member]
Product Information [Line Items]
Useful life of assets							7 years
Software and Software Development Costs [Member] \| Minimum [Member]
Product Information [Line Items]
Useful life of assets							5 years
Software and Software Development Costs [Member] \| Maximum [Member]
Product Information [Line Items]
Useful life of assets							7 years
Customer A [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage							25.00%	36.00%
Customer B [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage							19.00%	21.00%
Customer C [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage							17.00%	16.00%
Customer D [Member] \| Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage							11.00%	11.00%
Financing Agreement Amendment No. 6 [Member]
Product Information [Line Items]
Minimum cash balance requirement under credit agreement before adjustment										$ 60,000,000
Minimum cash balance requirement under credit agreement										$ 45,000,000
BIJUVA [Member]
Product Information [Line Items]
Inventory charge							$ 7,204,818
ANNOVERA [Member]
Product Information [Line Items]
Return period of unsalable prescription products							12 months
ANNOVERA [Member] \| Council License Agreement [Member]
Product Information [Line Items]
Milestone payment upon FDA Approval							$ 20,000,000
Milestone payments (payment after release of first commercial batch)							20,000,000
License rights acquired							20,000,000
Milestone payments upon specified levels of cumulative net sales							40,000,000
Specified level one of cumulative net sales for milestone payments							200,000,000
Specified level two of cumulative net sales for milestone payments							400,000,000
Specified level three of cumulative net sales for milestone payments							$ 1,000,000,000
Vitamins, IMVEXXY and BIJUVA [Member]
Product Information [Line Items]
Shelf life of prescription products							24 months
BIJUVA and ANNOVERA [Member]
Product Information [Line Items]
Shelf life of prescription products							18 months
BIJUVA and ANNOVERA [Member] \| Knight License Agreement [Member]
Product Information [Line Items]
Milestone payment received upon regulatory approval							$ 2,000,000
BIJUVA and ANNOVERA [Member] \| License Agreement Theramex [Member]
Product Information [Line Items]
Quarterly royalty payments percentage				5.00%